Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial

Introduction There is an unmet clinical need for the development of novel treatment strategies to improve the outcome of children with frequent relapsing or steroid-dependent nephrotic syndrome. Obinutuzumab (OBI) is a second-generation anti-CD20 monoclonal antibody that has demonstrated its superio...

Description complète

Détails bibliographiques

Auteurs principaux:	Florentia Kaguelidou, Julien Hogan, Anne-Laure Sellier-Leclerc, Isabelle Vrillon, Olivia Boyer, Sophie Guilmin-Crepon, Claire Dossier, Thomas Simon, Marc Fila, Cyrielle Parmentier, Charlotte Samaille, Gwenaelle Roussey-Kesler, Marie Magnavacca, Yannis Chartier, Ferielle Louillet, Ariane Zaloszyc, Djamel Elaribi, Sabrina Bouatia
Format:	Artigo
Langue:	Inglês
Publié:	BMJ Publishing Group 2025-12-01
Collection:	BMJ Open
Accès en ligne:	https://bmjopen.bmj.com/content/15/12/e111980.full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!